Roche's Hemophilia A Drug Positive In Second Phase III Study
Zacks Investment Research | Apr 17, 2017 06:36AM ET
Roche Holding (SIX:ROG) AG’s (OTC:RHHBY) unit Genentech announced positive interim results from the Phase III HAVEN 2 study evaluating its pipeline candidate emicizumab prophylaxis. Emicizumab was being assessed in children less than 12 years of age with hemophilia A and inhibitors to factor VIII.
The study revealed that emicizumab reduced the number of bleeds in children with hemophilia A and inhibitors to factor VIII after 12 weeks of treatment over time.
Roche’s share price shows that the company has outperformed the Zacks classified industry year to date. The stock rallied 11.8% compared with the Large Cap Pharmaceuticals industry’s gain of 5.4% during the period.
Notably, the results were in line with data from the phase III HAVEN 1 study in adults and adolescents (12 years of age or older) for the same indication. The data from the study announced in Dec 2016 showed a statistically significant reduction in the number of bleeds over time in patients treated with emicizumab prophylaxis as compared to those patients who do not receive prophylactic treatment.
Going forward, data from both HAVEN 1 and the interim results from HAVEN 2 studies will be presented at an upcoming medical meeting and submitted toregulatory authorities in order to get an approval.
Roche has been in the news this month for data-readouts and regulatory updates.
Last week, Roche announced that the global randomized phase III study, ALEX, on lung cancer drug Alecensa met its primary endpoint as an initial (first-line) treatment. According to the evaluation, Alecensa significantly reduced the risk of disease worsening or death (progression-free survival, PFS) compared with Pfizer’s (NYSE:PFE) Xalkori in patients suffering from anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).
Also, earlier this month, Roche announced encouraging results from another phase III study, ALUR Alecensa. This study also met its primary endpoint as data from the study demonstrated that Alecensa significantly improved progression-free survival (PFS) in patients. Importantly, last month, Roche received FDA approval for its highly-awaited multiple sclerosis (MS) drug, Ocrevus, which is expected to have blockbuster potential.
Get The News You Want
Zacks Rank & Key Picks
Roche currently sports a Zacks Rank #1 (Strong Buy). Other top-ranked stocks in the health care sector include Heska Corp. (NASDAQ:HSKA) and Galena Biopharma, Inc. (NASDAQ:GALE) . Both the companies carry Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here .
Heska’s earnings estimates moved up from $1.53 to $1.65 for 2017 and from $1.90 to $2.01 for 2018, over the last 60 days. The company posted a positive earnings surprise in all of the last four quarters, with an average beat of 291.54%. Its share price increased 41.9% year to date.
Galena Biopharma‘s loss estimates narrowed from $2.27 to 58 cents for 2017 and from 92 cents to 73 cents for 2018, over the last 60 days. The company posted a positive earnings surprise in two of the four trailing quarters with an average beat of 53.83%.
Sell These Stocks. Now.
Just released, today's 220 Zacks Rank #5 Strong Sells demand urgent attention. If any are lurking in your portfolio or Watch List, they should be removed immediately. These are sinister companies because many appear to be sound investments. However, from 1988 through 2016, stocks from our Strong Sell list have actually performed 6X worse than the S&P 500. Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.